The ECHELON-2 trial: results of a randomized, double-blind, active-controlled phase 3 Study of brentuximab vedotin and CHP (A plus CHP) versus CHOP in the frontline treatment of patients with CD30+peripheral T-Cell lymphomas
Authors
Horwitz, MO'Connor, A
Pro, B
Illidge, Timothy M
Fanale, A
Advani, H
Bartlett, L
Christensen, H
Morschhauser, F
Domingo-Domenech, E
Rossi, G
Kim, S
Feldman, A
Lennard, A
Belada, D
Illes, A
Tobinai, K
Tsukasaki, K
Yeh, P
Shustov, R
Huttmann, A
Savage, J
Yuen, S
Zinzani, L
Hua, W
Little, M
Rao, B
Woolery, J
Manley, T
Trumper, L
Affiliation
Department of Hematology and Transplantation, Hôpital Saint Louis, Colombes, FranceIssue Date
2018
Metadata
Show full item recordCitation
Horwitz S, O'Connor O, Pro B, Illidge TM, Fanale M, Advani R, et al. The ECHELON-2 trial: results of a randomized, double-blind, active-controlled phase 3 Study of brentuximab vedotin and CHP (A plus CHP) versus CHOP in the frontline treatment of patients with CD30+peripheral T-Cell lymphomass. Blood. 2018;132.#10.1182/blood-2018-99-110563Journal
BloodDOI
10.1182/blood-2018-99-110563Additional Links
https://dx.doi.org/10.1182/blood-2018-99-110563Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-99-110563